Through the co-citation timeline, we found that research on targeted therapy in AML had changed to venetoclax resistance (cluster #0), novel therapy (cluster #3), and FLT3 mutation (cluster #4) over the past decade. The gene discussed is FLT3; the disease is acute myeloid leukemia.